Down-regulation of human alloimmune responses by genetically engineered expression of CD95 ligand on stimulatory and target cells

European Journal of Immunology

Volumn 31, Issue 7, 2001, Pages 2217-2226

  Dulat, Holger J ^a   Von Grumbkow, Claudia ^a   Baars, Wiebke ^a   Schrder, Natalia ^a   Wonigeit, Kurt ^a   Schwinzer, Reinhard ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Apoptosis; Human; T lymphocyte; Tolerance suppression; Transplantation

Indexed keywords

APOPTOSIS INDUCING FACTOR; CHROMIUM 51; FAS LIGAND; INTERLEUKIN 2 RECEPTOR;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL PROTECTION; CHROMIUM 51 RELEASE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DOWN REGULATION; EFFECTOR CELL; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREACTIVITY; IN VITRO STUDY; LYMPHOCYTE CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; STEM CELL; T LYMPHOCYTE; TARGET CELL; TRANSPLANTATION;

APOPTOSIS; CELL LINE; CELLS, CULTURED; CYTOTOXICITY TESTS, IMMUNOLOGIC; DOWN-REGULATION; FAS LIGAND PROTEIN; GENETIC ENGINEERING; HUMANS; IMMUNE TOLERANCE; ISOANTIGENS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 0034937710     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4141(200107)31:7<2217::AID-IMMU2217>3.0.CO;2-E     Document Type: Article

References (30)

1. Unraveling immune privilege
2. Fas ligand-induced apoptosis as a mechanism of immune privilege
3. Apoptosis, graft rejection, and transplantation tolerance
4. A role for CD95 ligand in preventing graft rejection
5. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice
6. Fas ligand gene transfer to renal allografts in rats. Effects on allograft survival
7. Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration, but does not confer immune privilege upon islet allografts
8. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction
9. Transplantation of CD95 ligand-expressing grafts. Influence of transplantation site and difficulty in protecting allo- and xenografts
10. Accelerated rejection of fas ligand-expressing heart grafts
11. Fas-ligand: Privilege and peril
12. FasL - Too much of a good thing?
13. Apoptosis of mouse naive T cells induced by recombinant soluble fas ligand and activation-induced resistance to fas ligand
14. Membrane fas ligand kills human peripheral blood T lymphocytes, and soluble fas ligand blocks the killing
15. T cell receptor signals enhance susceptibility to Fas-mediated apoptosis
16. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood
17. Monoclonal antibody-mediated tumor regression by induction of apoptosis
18. Metalloproteinase-mediated release of human fas ligand
19. Lymphocyte apoptosis induced by CD95 (Apo-1/fas) ligand-expressing tumor cells - A mechanism of immune evasion?
20. Lyphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface
21. Activation interferes with the Apo-1 pathway in mature human T cells
22. + T cell-mediated cytotoxicity
23. Multiple target cell killing by the cytolytic T lymphocyte and the mechanism of cytotoxicity
24. Induction of antigen-specific immunosuppression by CD95L cDNA-transfected killer dendritic cells
25. Dendritic cells genetically engineered to express fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival
26. Induction of specific T cell tolerance by fas ligand-expressing antigen-presenting cells
27. Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo
28. Cutting edge: Chemotactic activity of soluble fas ligand against phagocytes
29. Regulation of the proinflammatory effects of fas ligand (CD95L)
30. CD28-mediated activation of resting human T cells without costimulation of the CD3/TCR complex